

# Oestrogens for preventing recurrent urinary tract infection in postmenopausal women (Review)

Perrotta C, Aznar M, Mejia R, Albert X, Ng CW



**THE COCHRANE  
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2008, Issue 2

<http://www.thecochranelibrary.com>



## TABLE OF CONTENTS

ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
BACKGROUND . . . . .	2
OBJECTIVES . . . . .	2
CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW . . . . .	2
SEARCH METHODS FOR IDENTIFICATION OF STUDIES . . . . .	3
METHODS OF THE REVIEW . . . . .	3
DESCRIPTION OF STUDIES . . . . .	4
METHODOLOGICAL QUALITY . . . . .	5
RESULTS . . . . .	5
DISCUSSION . . . . .	6
AUTHORS' CONCLUSIONS . . . . .	7
POTENTIAL CONFLICT OF INTEREST . . . . .	7
ACKNOWLEDGEMENTS . . . . .	7
SOURCES OF SUPPORT . . . . .	7
REFERENCES . . . . .	8
TABLES . . . . .	9
Characteristics of included studies . . . . .	9
Characteristics of excluded studies . . . . .	13
ADDITIONAL TABLES . . . . .	14
Table 01. Electronic search strategies . . . . .	14
ANALYSES . . . . .	15
Comparison 01. Oral oestrogens versus placebo . . . . .	15
Comparison 02. Vaginal oestrogens versus placebo/no treatment . . . . .	15
Comparison 03. Vaginal oestrogens versus antibiotics . . . . .	15
COVER SHEET . . . . .	15
GRAPHS AND OTHER TABLES . . . . .	16
Analysis 01.01. Comparison 01 Oral oestrogens versus placebo, Outcome 01 UTI at the end of the treatment period . . . . .	16
Analysis 01.02. Comparison 01 Oral oestrogens versus placebo, Outcome 02 Vaginal pH . . . . .	17
Analysis 01.03. Comparison 01 Oral oestrogens versus placebo, Outcome 03 Lactobacillus positive . . . . .	17
Analysis 01.04. Comparison 01 Oral oestrogens versus placebo, Outcome 04 All adverse events . . . . .	17
Analysis 02.01. Comparison 02 Vaginal oestrogens versus placebo/no treatment, Outcome 01 UTI at the end of the treatment period . . . . .	18
Analysis 02.02. Comparison 02 Vaginal oestrogens versus placebo/no treatment, Outcome 02 Vaginal pH . . . . .	18
Analysis 02.03. Comparison 02 Vaginal oestrogens versus placebo/no treatment, Outcome 03 Lactobacillus positive . . . . .	18
Analysis 02.04. Comparison 02 Vaginal oestrogens versus placebo/no treatment, Outcome 04 Any adverse events . . . . .	19
Analysis 03.01. Comparison 03 Vaginal oestrogens versus antibiotics, Outcome 01 UTI . . . . .	19
Analysis 03.02. Comparison 03 Vaginal oestrogens versus antibiotics, Outcome 02 Vaginal pH . . . . .	20
Analysis 03.03. Comparison 03 Vaginal oestrogens versus antibiotics, Outcome 03 Lactobacillus positive . . . . .	20
Analysis 03.04. Comparison 03 Vaginal oestrogens versus antibiotics, Outcome 04 Adverse events (burning, itching or vaginal bleeding) . . . . .	21

# Oestrogens for preventing recurrent urinary tract infection in postmenopausal women (Review)

Perrotta C, Aznar M, Mejia R, Albert X, Ng CW

## This record should be cited as:

Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. *Cochrane Database of Systematic Reviews* 2008, Issue 2. Art. No.: CD005131. DOI: 10.1002/14651858.CD005131.pub2.

**This version first published online:** 16 April 2008 in Issue 2, 2008.

**Date of most recent substantive amendment:** 31 January 2008

## ABSTRACT

### Background

Recurrent urinary tract infection (RUTI) is defined as three episodes of urinary tract infection (UTI) in the previous 12 months or two episodes in the last six months. The main factors associated with RUTI in postmenopausal women are vesical prolapse, cystocele, post-voidal residue and urinary incontinence, all associated with a decrease in oestrogen. The use of oestrogens to prevent RUTI has been proposed.

### Objectives

To estimate the efficacy and safety of oral or vaginal oestrogens for preventing RUTI in postmenopausal women.

### Search strategy

We searched the Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1950), EMBASE (from 1980), reference lists of articles without language restriction.

*Date of last search: February 2007.*

### Selection criteria

Randomised controlled trials (RCTs) in which postmenopausal women (more than 12 months since last menstrual period) diagnosed with RUTI received any type of oestrogen (oral, vaginal) versus placebo or any other intervention were included.

### Data collection and analysis

Authors extracted data and assessed quality. Statistical analyses were performed using the random effects model and the results expressed as relative risk (RR) for dichotomous outcomes or mean difference (WMD) for continuous data with 95% confidence intervals (CI).

### Main results

Nine studies (3345 women) were included. Oral oestrogens did not reduce UTI compared to placebo (4 studies, 2798 women: RR 1.08, 95% CI 0.88 to 1.33). Vaginal oestrogens versus placebo reduced the number of women with UTIs in two small studies using different application methods. The RR for one was 0.25 (95% CI 0.13 to 0.50) and 0.64 (95% CI 0.47 to 0.86) in the second. Two studies compared oral antibiotics versus vaginal oestrogens (cream (1), pessaries (1)). There was very significant heterogeneity and the results could not be pooled. Vaginal cream reduced the proportion of UTIs compared to antibiotics in one study and in the second study antibiotics were superior to vaginal pessaries. Adverse events for vaginal oestrogens were breast tenderness, vaginal bleeding or spotting, nonphysiologic discharge, vaginal irritation, burning and itching.

### Authors' conclusions

Based on only two studies comparing vaginal oestrogens to placebo, vaginal oestrogens reduced the number of UTIs in postmenopausal women with RUTI, however this varied according to the type of oestrogen used and the treatment duration.

## PLAIN LANGUAGE SUMMARY

Recurrent urinary tract infection (RUTI) is defined as three episodes of urinary tract infection (UTI) in the previous 12 months or two episodes in the last six months. In postmenopausal women the prevalence rate for having one episode of UTI in a given year varies from 8% to 10%. This increased risk is associated with a decrease in oestrogen levels. The use of oestrogens (orally or vaginally) has been proposed as a preventive strategy. This review identified nine studies (3345 women) treated with oestrogens versus placebo, no treatment or antibiotics. Vaginal oestrogens reduced the number of UTIs when compared to placebo. All studies reported adverse events for the oestrogen treatment groups. These included breast tenderness, vaginal bleeding or spotting, vaginal discharge, vaginal irritation, burning and itching.

## BACKGROUND

Recurrent urinary tract infection (RUTI) is defined as three episodes of urinary tract infection (UTI) in the previous 12 months or two episodes in the last six months. In postmenopausal women the prevalence rate for having one episode of UTI in a given year varies from 8% to 10%. Of those women who have an episode, 5% will experience a recurrence within the year (Brown 1999; Foxman 2000).

In premenopausal women the main risk factors associated with RUTI are frequency of sexual intercourse, the use of spermicides, the age at first UTI (less than 15 years of age indicates a greater risk of RUTI) and a history of UTI in the mother. After menopause the main risk factors are vaginal prolapse, cystocele, post-voidal residue, changes in vaginal flora, and urinary incontinence (Foxman 2000; Raz 2000). Weaker associations have been found with non-secretor status and a history of UTI before menopause. The association of RUTI with sexual habits, such as frequency of sexual intercourse and the use of spermicides is not as positive as in younger women. No association were found in a study by Foxman 2001 and in another case controlled study, sexually active women had an odds ratio (OR) of 1.42 (95% CI 1.07 to 1.87) of having RUTIs over non-sexually active women (Hu 2004).

Several approaches have been proposed for the prevention of RUTI. A Cochrane systematic review showed that antibiotics are effective in reducing the number or recurrences. However, adverse events were common and compliance with treatment varied (Albert 2004). Cranberry juice or cranberry pills has some effect as a preventive strategy (Jepson 2004).

During the last few decades there has been an increasing interest in the treatment with local or oral oestrogens for the prevention of UTI and urinary symptoms in postmenopausal women. Basic research has demonstrated that oestrogens receptors are present in the vagina, urethra, the trigone of the bladder and pelvic floor musculature. It is believed that they play a crucial role in the continence mechanism (Iosif 1981; Robinson 2003).

Vaginal flora changes with the reduction of local and circulating oestrogens during menopause. Vaginal pH rises after and vaginal *Lactobacillus* decrease, allowing gram negative bacteria to grow

and act as uropathogen. A Cochrane systematic review (Suckling 2006) concluded that vaginal estrogens improve vaginal atrophgia and increase vaginal *Lactobacillus*. A Cochrane systematic review by Moehrer 2004 reported that oestrogens are effective in the subjective impression of cure in women with urinary incontinence, and that increase as well the presence of *Lactobacillus* and vaginal pH decrease. Given this evidence oestrogens have been proposed as a strategy for the prevention of UTI in postmenopausal women. Several methods of administration have been tested: oral, vaginal cream, vaginal tablets, vaginal ring and vaginal pessaries.

However some controversy surrounds the use of oestrogens in RUTI. While it appears that vaginal oestrogens decrease UTI occurrence, oral oestrogens apparently do not have this effect. In addition, there is concern in relation to its long term use and the adverse events associated with them. There is also some evidence suggesting oral antibiotics have a higher efficacy as a preventing strategy for RUTI than local oestrogen use (Raz 2001).

## OBJECTIVES

To examine the efficacy of oestrogens (oral or vaginal) in decreasing the rate of RUTI in postmenopausal women and their safety (in terms of systemic or local adverse events such as allergic reactions or local irritation).

## CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW

### Types of studies

We included randomised controlled trials (RCTs) and quasi randomised-RCTs (in which allocation to treatment was obtained by alternation, medical record numbers, date of birth or other predictable methods).

### Types of participants

All postmenopausal women (more than 12 months since last menstrual period) with RUTIs (defined as three UTI episodes in the last 12 months or two episodes in the last six months) where at

least one UTI outcome was assessed. There were no exclusions based on other underlying disease or urinary tract abnormality.

### Types of intervention

Oral oestrogens (with or without progestogens), or vaginal oestrogens (delivered by cream, vaginal ring, vaginal pessaries, vaginal tables or any other formulation) given at any dose or any length of treatment used as a preventive strategy for the reduction of RUTI versus:

- Placebo.
- Another type of oestrogen delivery (e.g. oral versus local, cream versus vaginal ring, vaginal ring versus vaginal pessaries).
- Another preventive strategy (e.g. antibiotic, cranberry juice).
- No treatment.

We excluded those studies that only included assessment of vaginal atrophy as this has been covered in another Cochrane review (Suckling 2006).

### Types of outcome measures

#### Primary outcomes

- Women with RUTIs at the end of active treatment period.
- UTIs at the end active treatment period.
- Time until recurrence.
- Number of urinary infections/person/year.
- Number of asymptomatic women at the end of the study.
- Number of relapsing after the end of the study.

#### Secondary outcomes

- Proportion of women *Lactobacillus* positive.
- Vaginal pH at the end of the active treatment period.

#### Adverse events

- Proportion of severe adverse events (resulting in the cessation of treatment).
- Proportion of referred adverse events.
- Endometrial thickness at the end of the active treatment period.
- Proportion of women with vaginal bleeding or spotting.
- Proportion of women with breast tenderness.

## SEARCH METHODS FOR IDENTIFICATION OF STUDIES

See: Cochrane Renal Group methods used in reviews.

We searched the following electronic bibliographic databases (see Table 01 - *Electronic search strategies*)

- The Cochrane Renal Group's specialised register and the Cochrane Central Register of Controlled Trials (CENTRAL) in *The Cochrane Library* (issue 1, 2007). CENTRAL and the Renal Groups Specialised Register contain the handsearched results of conference proceedings from general and speciality meetings. This is an ongoing activity across the Cochrane Collaboration and is both retrospective and prospective (Master List 2007). Therefore we did not specifically search conference proceedings.
- MEDLINE (1950 to February 2007) using the optimally sensitive strategy developed for the Cochrane Collaboration for the identification of RCTs (Dickersin 1994) with a specific search strategy developed with input from the Cochrane Renal Group Trial Search Coordinators.
- EMBASE (1980 to February 2007) using a search strategy adapted from that developed for the Cochrane Collaboration for the identification of RCTs (Lefebvre 1996) together with a specific search strategy developed with input from the Cochrane Renal Group Trial Search Coordinators.
- Lilacs (1988 to February 2007).
- Reference list of retrieved articles.
- Communication with authors for clarification of results and/or methods. We contacted Kjaergaard 1990, but could not reach the investigators from Xu 2001.

## METHODS OF THE REVIEW

### Study selection

Two authors (CP, CW) independently screened the initial search results of all the databases and references lists to identify citations relevant to our review. Once identified the abstracts were checked and full text articles obtained when inclusion criteria were met.

### Quality assessment

Each RCT was evaluated by two authors (CW, MA) and a third author (CP) resolved discrepancies.

### Allocation concealment

- Adequate (A): Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study.
- Unclear (B): Randomisation stated but no information on method used is available.
- Inadequate (C): Method of randomisation used such as alternate medical record numbers or unsealed envelopes; any information in the study that indicated that investigators or participants could influence intervention group.

### Blinding

- Blinding of investigators: Yes/no/not stated.
- Blinding of participants: Yes/no/not stated.
- Blinding of outcome assessor: Yes/no/not stated.
- Blinding of data analysis: Yes/no/not stated.

The above are considered not blinded if the treatment group can be identified in > 20% of participants because of the side effects of treatment.

### Intention-to-treat analysis

- Yes: Specifically reported by authors that intention-to-treat analysis was undertaken and this was confirmed on study assessment.
- Yes: Not stated but confirmed on study assessment.
- No: Not reported and lack of intention-to-treat analysis confirmed on study assessment. (Women who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study or were not included because of protocol violation).
- No: Stated but not confirmed upon study assessment.
- Not stated.

### 4. Completeness of follow-up

Number of participants with data/number of participants randomised, expressed as a percentage overall and in each intervention group.

We evaluated outcome definitions (how the authors defined clinical and microbiological recurrences) and the ways in which adverse events were recalled. Discrepancies in those definitions and assessments were taken into consideration while doing the analysis especially if heterogeneity was identified.

### Data analysis

Data was extracted using a data extraction form (CW, MA) and then entered into RevMan. CP checked the original papers for discrepancies. Dichotomous outcomes were analysed as relative risk (RR) and 95% confidence interval (CI). The time until recurrence was intended to be done using Kaplan-Meier method. However, because we could not contact the authors to obtain individual data from each of the studies, we have reported the results from each study individually. Continuous variables were analysed using mean differences (WMD) and 95% CI. We used random-effects model to assess overall treatment effects. Heterogeneity was analysed using a chi squared test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and the I<sup>2</sup> test (Higgins 2003). I<sup>2</sup> values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. When heterogeneity was found we did subgroup analysis according to the intervention, study design (RCT and quasi-RCTs) and blinding.

## DESCRIPTION OF STUDIES

We identified 17 potential studies from the search strategy. We excluded eight studies (Ayton 1996; Brandberg 1987; Chom-pootaweep 1998; Henriksson 1996; Marx 2004; Molander 1990; Notelovitz 1995; Orlander 1992) because they only reported on vaginal atrophy which has been covered by another Cochrane review (Suckling 2006) or the population did not have to have had a previous UTI. Nine studies (3345 women) met our inclusion criteria (Brown 2001; Cardozo 1998; Eriksen 1999; Kirkengen 1992; Kjaergaard 1990; Ouslander 2001; Raz 1993; Raz 2003; Xu 2001) (see table: *Characteristics of included studies*).

### Interventions

- Oral oestrogens versus placebo (Brown 2001; Cardozo 1998; Kirkengen 1992; Ouslander 2001).
- Vaginal oestrogens versus placebo (Kjaergaard 1990; Eriksen 1999; Raz 1993).
- Vaginal oestrogens versus antibiotics (Raz 2003; Xu 2001).

### Reported outcomes

#### Oral oestrogens versus placebo

- Proportion of two or more UTIs during first, second, third and fourth year of treatment as reported by the participants answering the question: "During the past year, how many times has a doctor told you that you had a urinary tract infection?" (Brown 2001).
- The proportion of women who developed at least one UTI during the study period (Cardozo 1998).
- The percentage of vaginal superficial cells, vaginal pH, vaginal parabasal cells, bacteriuria and pyuria, and presence of *Lactobacillus* (Ouslander 2001).
- Proportion of women with two UTIs at the end of treatment period and vaginal pH (Kirkengen 1992).

#### Vaginal oestrogens versus placebo

- Women were evaluated once a month for five months to evaluate the number of positive cultures and patient satisfaction (Kjaergaard 1990).
- Proportion of women with RUTI and proportion of women remaining free of UTI, vaginal atrophy and vaginal pH (Eriksen 1999).
- Incidence of UTI, proportion of women remaining free of UTI and number of episodes of UTI/patient/year, presence of *Lactobacillus* and vaginal pH (Raz 1993).

#### Vaginal oestrogens versus antibiotics

- Number of UTI episodes/patient/year, the proportion of women who remained free of UTI, percentage of superficial cells and the presence of *Lactobacillus* (Raz 2003).

- Proportion of women with UTI at the end of the study period, adverse events and vaginal atrophy (Xu 2001).

## METHODOLOGICAL QUALITY

Overall, the quality of the included studies were good.

### Allocation concealment

One study had adequate allocation concealment (Brown 2001) and the rest were unclear. In the study by Xu 2001 it was not clear why the two groups were unbalanced (oestriol group  $n = 30$ ; antibiotic group  $n = 15$ ).

### Blinding

Eight studies were 'double blind'. Eriksen 1999 had a no treatment control group and the women and investigators were therefore not blinded.

### Intention-to-treat

All studies analysed by intention-to-treat. Eriksen 1999 also analysed 'per-protocol'.

### Completeness of follow-up

- Cardozo 1998: Twenty-two women were unable to complete the study. Reasons for early discontinuation in the oestriol group ( $n = 13$ ) were major protocol violation ( $n = 4$ ); hospital admission ( $n = 2$ ); bleeding ( $n = 2$ ); cerebrovascular accident ( $n = 2$ ); poor compliance; adverse experiences; and depression. Early discontinuation reasons in the placebo group ( $n = 9$ ) included femur fracture ( $n = 2$ ); poor compliance; major protocol violation; septicaemia; cerebrovascular accident; left arm paresis; adverse experiences and general decline in health.
- Eriksen 1999: Five subjects (9%) withdrew from the ring group and 1 subject (2%) withdrew from the control group before completion of the 36-week study period or before first recurrence (control group).
- Ouslander 2001: Three (9%) dropped out before the 3-month examination (two active, one placebo), leaving 29 subjects who had 3-month measures (13 active and 16 placebo; 91% of those enrolled). An additional eight (25%) dropped out before the 6-month examination (four active, four placebo), leaving 21 subjects who had 6-month measures (nine active and 12 placebo; 66% of those enrolled). Reasons for dropping out were primarily various acute illnesses (which resulted in two deaths).
- Raz 1993: reasons for early withdrawal from the study: side effects in 10 women in the oestriol group and 4 in the placebo group; lack of compliance with follow-up in 3 and 5 women, respectively; death due to myocardial infarction in 1 oestriol-treated patient; and failure to respond to topical prophylaxis necessitating systemic antimicrobial prophylaxis for recurrent infections in 10 women in the placebo group.

- Raz 2001: Twenty-seven women in the oestriol group and 23 in the NM group dropped out. Reasons for dropout included adverse events (9 women in the oestriol group and 14 in the NM group), lack of compliance with the treatment regimen (13 and 6, respectively), and intermittent illness (3 and 2, respectively).

## RESULTS

### Oral oestrogens versus placebo (comparison 01)

#### *Proportion of women with UTI at the end of the treatment period (analysis 01.01)*

Four studies assessed this outcome (Brown 2001; Cardozo 1998; Kirkengen 1992; Ouslander 2001). There was no significant difference in the number of women with UTI at the end of the treatment period between oral oestrogens and placebo (4 studies, 2798 women: RR 1.08, 95% CI 0.88 to 1.33;  $I^2 = 0\%$ ).

#### *Vaginal pH (analysis 01.02)*

Two studies reported the change in vaginal pH (Kirkengen 1992; Ouslander 2001). There was a significant decrease in vaginal pH with the oral oestrogens (2 studies, 62 women: WMD -1.00, 95% CI -1.43 to -0.57;  $I^2 = 0\%$ ).

#### *Proportion of women Lactobacillus positive (analysis 01.03)*

One study (Ouslander 2001) reported this outcome. There was no significant difference between the two groups in the number of women who were *Lactobacillus* positive (1 study, 32 women: RR 10.13, 95% CI 0.59 to 173.83).

#### *All adverse events (analysis 01.04)*

Two studies reported adverse events that occurred during the treatment period. Cardozo 1998 reported breast tenderness and mild vaginal bleeding, and Ouslander 2001 reported vaginal spotting and mild breast discomfort (present in minority, however number not reported). There were significantly less adverse events in the placebo group (2 studies, 104 women: RR 5.11, 95% CI 1.39 to 18.76;  $I^2 = 0\%$ ).

#### *Other outcomes reported*

Cardozo 1998 reported 34% women free of infection in the oestriol group at the end of the study period (12 months) versus 44% in the placebo group. The results were not statistically significant.

### Vaginal oestrogens versus placebo (comparison 02)

#### *Proportion of infection at the end of the treatment period (analysis 02.01)*

Two studies (Eriksen 1999, Raz 1993) reported this outcome. We did not pool these studies as there was significant heterogeneity. The heterogeneity could be explained by the type of application method used. Raz 1993 compared topically applied intravaginal oestriol cream oestrogens to placebo cream while Eriksen 1999 compared releasing silicone vaginal ring (Estring) (2 mg oestriol) with no treatment control group. The RR for Raz 1993, was 0.25

(95% CI 0.13 to 0.50) and in Eriksen 1999, the RR was 0.64 (95% CI 0.47 to 0.86).

#### **Vaginal pH (analysis 02.02)**

Raz 1993 reported a significant decrease in pH with vaginal oestrogens (93 women: WMD -2.50, 95% CI -3.16 to -1.84).

#### **Proportion of women *Lactobacillus* positive (analysis 02.03)**

Raz 1993 reported significantly more women were *Lactobacillus* positive in the vaginal oestrogen group (93 women: RR 38.82, 95% CI 2.42 to 621.60).

#### **All adverse events (analysis 02.04)**

The adverse events included vaginal bleeding and nonphysiologic discharge (Eriksen 1999), and vaginal irritation, burning, or itching (Raz 1993). There was no significant difference in adverse events between the two groups (201 women: RR 4.72, 95% CI 0.67 to 33.53;  $I^2 = 67.5\%$ ), however there was moderate heterogeneity. The control group in Eriksen 1999 received no treatment and the control group in Raz 1993 received a placebo cream.

#### **Other outcomes**

- Eriksen 1999 reported that after 9 months the 45% of participants were free of UTIs in the oestrogen group and approximately 20% in the control group ( $P < 0.008$ ). In Raz 1993, the intervention group had a cumulative likelihood of remaining disease free of 0.95 and the placebo group 0.30 ( $P < 0.001$  log rank test).
- Raz 1993 reported the mean number of days of antibiotic use. The oestrogen group received antibiotics for 6.9 days ( $\pm 1.1$  SD) and the placebo group 32.0 days ( $\pm 7.8$ ) ( $P < 0.001$ ).
- Kjaergaard 1990 reported a median of 1.5 UTIs in the oestrogen group and 1 in the control group (range 0 to 5 for both groups). There were no differences in patient satisfaction.
- Eriksen 1999 reported 34 women (67%) in the Estring group and one (2%) in the control group were free of vaginal mucosal atrophy at the end of the treatment period.

#### **Vaginal oestrogens versus antibiotics (comparison 03)**

Two studies used different mode of administration. Raz 2003 used a vaginal pessary and Xu 2001 used vaginal cream.

#### **Proportion of women with UTIs at the end of the treatment period (analysis 03.01)**

The pooled results went in different directions and had significant heterogeneity. We have shown these results without the summary estimate.

- Raz 2003 (171 participants) reported significantly less UTIs in the antibiotic group compared to the oestrogen group (RR 1.30, 95% CI 1.01 to 1.68).
- Xu 2001 (42 women) reported significantly less UTIs in the oestrogen group compared the antibiotic group after three months

(RR 0.09, 95% CI 0.02 to 0.36). Two months after stopping treatment there was no significant difference in the number of women with RUTIs (RR 0.56, 95% CI 0.09 to 3.55).

#### **Vaginal pH (analysis 03.02)**

There was no statistical difference in vaginal pH between vaginal oestrogens and antibiotics ((2 studies, 213 women: WMD -1.69, 95% CI -4.24 to 0.85;  $I^2 = 99.3\%$ ), however there was very significant heterogeneity.

#### **Proportion of women *Lactobacillus* positive (analysis 03.03)**

There was no statistical difference in the number of women *Lactobacillus* positive between vaginal oestrogens and antibiotics (2 studies, 213 women: RR 4.02, 95% CI 0.25 to 65.06;  $I^2 = 75.1\%$ ). There was significant heterogeneity.

#### **Adverse events (analysis 03.04)**

- Xu 2001 reported that in the oestrogen group five reported burning, two reported itching. Doses were decreased and three dropped out of the study. There were no reported side effects for the antibiotic group.
- In Raz 2003 the adverse events were more frequent in the vaginal estrogens group, 36% for all adverse events and 16% for drug-related adverse events. In those women receiving oestriol the adverse events were itching, burning, vaginal discharge and metrorrhagia.

## **DISCUSSION**

### **Oral oestrogens versus placebo**

Oral oestrogens did not reduce the occurrence of RUTI or the number of postmenopausal women who were *Lactobacillus* positives. There was a significant decrease in vagina pH and significantly more women reported adverse events (breast tenderness, mild vaginal bleeding and spotting) in the group treated with oral oestrogens.

### **Vaginal oestrogens versus placebo**

There was a reduction on the number of UTIs in the vaginal oestrogens group in two studies. The two studies used different type of application method (Raz 1993 used topical vaginal cream and Eriksen 1999 used releasing silicone vaginal ring (Estring) (2 mg oestriol) that it is likely to explain the heterogeneity in the pool analysis. Both trials have a reduction in the proportion of UTIs. The RR for Raz 1993, was 0.25 (95% CI 0.13 to 0.50) and in Eriksen 1999, the RR was 0.64 (95% CI 0.47 to 0.86).

### **Vaginal oestrogens versus antibiotics**

When pooling the results from the two studies that compared antibiotics and vaginal oestrogens, the differences in magnitude and direction of effects and the subsequent heterogeneity while pooling these two studies should be noted. One possible explanation is the use different types of vaginal oestrogens, Raz 2003 used a

vaginal pessary and Xu 2001 vaginal cream. Raz 2003 discussed in his paper the small effect of oestrogens compared to nitrofurantoin and the paper suggest that the use of vaginal pessaries could have been less effective than the use of cream. It seems that the oestrogens administration form may have had an impact on its effect on the vaginal mucosa. It is of notice the high number of infections under the antibiotics arm in the Xu 2001 study. It is unclear the reason for this high number of infections in this group.

Evidence from two small studies shows that in postmenopausal women with RUTI, vaginal oestrogens reduce the number of UTIs. However the true magnitude of the effect is difficult to assess as the two studies used different type of vaginal oestrogens and different type of comparators. The significant heterogeneity seen in this comparison means it is not appropriate to pool these data.

The type of vaginal oestrogens to use is unclear; while cream seems more effective than vaginal ring, vaginal cream could be more difficult to apply for certain women and acceptability is lower compared to vaginal ring as it has to be applied every day to maintain the effect (Suckling 2006). Vaginal ring on the other hand is more expensive and requires a trained doctor to place correctly. The role for vaginal pessaries is unclear. In the study by Raz 2003 they were not effective in reducing the pH no increasing the presence of *Lactobacillus* or decreasing UTIs. Vaginal creams are possibly more suitable for outpatients and vaginal rings or pessaries could be used in nursing homes residents. Adverse events did occur more frequently in women receiving oestrogens comparing to placebo, no treatment or antibiotic. This issue must be discussed and anticipated with any potential patient as it may affect adherence to treatment. The effect of vaginal oestrogens on the reduction of UTIs could take at least 12 weeks (evaluating the time until recurrence or the time taken for the vaginal pH to decrease Eriksen 1999) and women should also be advised about this to avoid discontinuation of the treatment.

## AUTHORS' CONCLUSIONS

### Implications for practice

- In postmenopausal women with RUTI associated with a lack of oestrogens and signs and significant symptoms of vaginal atrophy, vaginal oestrogens are a potentially valid intervention. However, women should be advised that the evidence is based on only a few small studies.
- The type of oestrogens to use is less clear. Vaginal rings need to be changed periodically and have to be placed by an experienced doctor, however they could be an option in women who have difficulties in applying a cream or used in nursing home residents.

- Vaginal creams are a cheaper and possibly a more efficient option but women should be advised about adverse events (itching and burning, occasionally spotting).
- The studies comparing vaginal oestrogens to antibiotics were inconclusive due to the significant heterogeneity between the two studies.

### Implications for research

- Future research should focus first in confirm the results of these small studies. They will need to evaluate which type of vaginal delivery is the best option and the outcomes should include cost, patient satisfaction and duration of treatment.
- Is not clear how long treatment should be given, what is the best treatment schedule and what would be the long-term adverse consequences of sustaining this intervention for more than 8 months.
- Studies comparing antibiotics plus vaginal oestrogens and vaginal oestrogens and cranberry juice should be encouraged in addition to studies in different populations (e.g. outpatients and nursing home residents or geriatric population).

## POTENTIAL CONFLICT OF INTEREST

None declared.

## ACKNOWLEDGEMENTS

- Dr Shijun Zhou from the UCD School of Public Health and Cheen Werne Ng translated the Chinese paper.
- Dr Kirsten Doherty form the UCD School of Public Health translated the Danish paper.
- We wish to acknowledge the valuable comments and suggestions from the referees of this manuscript; Prof Hugo N. Catalano, Dr Andrew Hextall, Dr Raul Raz and Dr Nicole Vogt-Ferrier.

## SOURCES OF SUPPORT

### External sources of support

- No sources of support supplied

### Internal sources of support

- Health Research Board IRELAND
- Iberoamerican Cochrane Center, Barcelona SPAIN
- UCD School of Public Health and Population Sciences IRELAND

## REFERENCES

### References to studies included in this review

**Brown 2001** {published data only}

Brown JS, Vittinghoff E, Kanaya AM, Agarwal SK, Hulley S, Foxman B. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. *Obstetrics & Gynecology* 2001;**98**(6):1045–52. [MEDLINE: 11755552].

**Cardozo 1998** {published data only}

Cardozo L, Benness C, Abbott D. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. *British Journal of Obstetrics & Gynaecology* 1998;**105**(4):403–7. [MEDLINE: 9609266].

**Eriksen 1999** {published data only}

\*Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. *American Journal of Obstetrics & Gynecology* 1999;**180**(5):1072–9. [MEDLINE: 10329858].

**Kirkengen 1992** {published data only}

Kirkengen AL, Andersen P, Gjersoe E, Johannessen GR, Johnsen N, Bodd E. Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. *Scandinavian Journal of Primary Health Care* 1992;**10**(2):139–42. [MEDLINE: 1641524].

**Kjaergaard 1990** {published data only}

Kjaergaard B, Walter S, Knudsen A, Johansen B, Barlebo H. Treatment with low-dose vaginal oestradiol in post menopausal women. A double-blind controlled investigation [Behandling med lavdosis vaginal oestradiol hos postmenopausale kvinder]. *Ugeskr Laeger* 1990;**152**(10):658–9.

**Ouslander 2001** {published data only}

Ouslander JG, Greendale GA, Uman G, Lee C, Paul W, Schnelle J. Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. *Journal of the American Geriatric Society* 2001;**49**(6):803–7. [MEDLINE: 11454122].

**Raz 1993** {published data only}

Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. *New England Journal of Medicine* 1993;**329**(11):753–56. [MEDLINE: 8350884].

**Raz 2003** {published data only}

Raz R, Colodner R, Rohana Y, Battino S, Rottensterich E, Wasser I, et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. *Clinical Infectious Diseases* 2003;**36**(11):1362–8. [MEDLINE: 12766829].

**Xu 2001** {published data only}

Xu R, Wu Y, Hu Y. Prevention and treatment of recurrent urinary system infection with estrogen cream in postmenopausal women. *Chung-Hua Fu Chan Ko Tsa Chih [Chinese Journal of Obstetrics & Gynecology]* 2001;**36**(9):531–3. [MEDLINE: 11769665].

### References to studies excluded from this review

**Ayton 1996**

Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, et al. A comparative study of safety and efficacy of continu-

ous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. *British Journal of Obstetrics & Gynaecology* 1996;**103**(4):351–8. [MEDLINE: 8605133].

**Brandberg 1987**

Brandberg A, Mellstrom D, Samsioe G. Low dose oral estriol treatment in elderly women with urogenital infections. *Acta Obstetrica et Gynecologica Scandinavica - Supplement* 1987;**140**:33–8. [MEDLINE: 3475935].

**Chompootaweep 1998**

Chompootaweep S, Nunthapisud P, Trivijitsilp P, Sentrakul P, Dusitsin N. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study. *Clinical Pharmacology & Therapeutics* 1998;**64**(2):204–10. [MEDLINE: 9728901].

**Henriksson 1996**

Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. *American Journal of Obstetrics & Gynecology* 1996;**174**(1 Pt 1):85–92. [MEDLINE: 8572039].

**Marx 2004**

Marx P, Schade G, Wilbourn S, Blank S, Moyer D, Nett R. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. *Maturitas* 2004;**47**(1):47–54. [MEDLINE: 14706765].

**Molander 1990**

\*Molander U, Milsom I, Ekelund P, Mellstrom D, Eriksson O. Effect of oral estriol on vaginal flora and cytology and urogenital symptoms in the post-menopause. *Maturitas* 1990;**12**(2):113–20. [MEDLINE: 2255263].

**Notelovitz 1995**

Notelovitz M. Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration. *Maturitas* 1995;**22** Suppl:S31–3. [MEDLINE: 8775774].

**Orlander 1992**

Orlander JD, Jick SS, Dean AD, Jick H. Urinary tract infections and estrogen use in older women. *Journal of the American Geriatric Society* 1992;**40**(8):817–20. [MEDLINE: 1634725].

### Additional references

**Albert 2004**

Albert X, Huertas I, Pereiró I, Sanfélix J, Gosalbes V, Perrotta C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. *Cochrane Database of Systematic Reviews* 2004, Issue 3. Art. No.: CD001209. DOI: [10.1002/14651858.CD001209.pub2](https://doi.org/10.1002/14651858.CD001209.pub2).

**Brown 1999**

Brown JS, Grady D, Ouslander JG, Herzog AR, Varner RE, Posner SF. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. *Heart & Estrogen/Progestin Replacement*

- Study (HERS) Research Group. *Obstetrics & Gynecology* 1999;**94**(1): 66–70. [MEDLINE: 10389720].
- Dickersin 1994**  
Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. *BMJ* 1994;**309**(6964):1286–91. [MEDLINE: 7718048].
- Foxman 2000**  
Foxman B, Barlow R, D'Arcy H, Guillespie B, Sobel JD. Urinary tract infection: self reported incidence and associated costs. *Annals of Epidemiology* 2000;**10**(8):509–15. [MEDLINE: 11118930].
- Foxman 2001**  
Foxman B, Somsel P, Tallman P, Gillespie B, Raz R, Colodner R, et al. Urinary tract infection among women aged 40 to 65: Behavioral and sexual risk factors. *Journal of Clinical Epidemiology* 2001;**54**(7): 710–18. [MEDLINE: 11438412].
- Higgins 2003**  
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557–60. [MEDLINE: 12958120].
- Hu 2004**  
Hu KK, Boyko EJ, Scholes D, Normand E, Chen CL, Grafton J, et al. Risk factors for urinary tract infections in postmenopausal women. *Archives of Internal Medicine* 2004;**164**(9):989–93. [MEDLINE: 15136308].
- Iosif 1981**  
Iosif CS, Batra S, Ek A, Astedt B. Estrogen receptors in the human female lower urinary tract. *American Journal of Obstetrics & Gynecology* 1981;**141**(7):817–20. [MEDLINE: 7198384].
- Jepson 2004**  
Jepson RG, Mihaljevic L, Craig J. Cranberries for preventing urinary tract infections. *Cochrane Database of Systematic Reviews* 2004, Issue 2. Art. No.: CD001321. DOI: [10.1002/14651858.CD001321.pub3](https://doi.org/10.1002/14651858.CD001321.pub3).
- Lefebvre 1996**  
Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Fourth International Cochrane Colloquium; 1996 Oct 20–24; Adelaide (Australia). 1996.
- Master List 2007**  
United States Cochrane Center. Master list of journals being searched. <http://apps1.jhsph.edu/cochrane/masterlist.asp> (accessed May 2007).
- Moehrer 2004**  
Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. *Cochrane Database of Systematic Reviews* 2004, Issue 2. Art. No.: CD001405. DOI: [10.1002/14651858.CD001405](https://doi.org/10.1002/14651858.CD001405).
- Raz 2000**  
Raz R, Gennesin Y, Wasser J, Stoler Z, Rosenfeld S, Rottenstreich E, et al. Recurrent urinary tract infections in postmenopausal women. *Clinical Infectious Diseases* 2000;**30**(1):152–6. [MEDLINE: 10619744].
- Raz 2001**  
Raz R. Hormone replacement therapy or prophylaxis in postmenopausal women with recurrent urinary tract infection. *Journal of Infectious Diseases* 2001;**183** Suppl(1):74–6. [MEDLINE: 11171020].
- Robinson 2003**  
Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. *Urology* 2003;**62**(4 Suppl 1):45–51. [MEDLINE: 14550837].
- Suckling 2006**  
Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD001500. DOI: [10.1002/14651858.CD001500.pub2](https://doi.org/10.1002/14651858.CD001500.pub2).
- \*Indicates the major publication for the study

## TABLES

### Characteristics of included studies

Study	Brown 2001
Methods	Randomised, double-blinded controlled trial. 20 clinical centres in the US. Jan 1993 and Sep 1994. Follow-up: Mean of 4.1 years.
Participants	Number: 2763 postmenopausal women. Age: < 80 years old. Coronary heart disease and intact uterus.
Interventions	TREATMENT GROUP 0.625 mg of oral conjugated oestrogen plus 2.5 mg of medroxyprogesterone acetate.  CONTROL GROUP

**Characteristics of included studies (Continued)**

	Placebo.
Outcomes	1. Proportion with 2 or more UTIs during the 1st, 2nd, 3rd and 4th year of treatment (dichotomous).
Notes	Definition of RUTI: two or more UTIs. Logistic regression to examine the predictors of UTIs. Data not collected for this outcome (secondary analysis).
Allocation concealment	A – Adequate

**Study**                      **Cardozo 1998**

Methods	Double-blind, randomised, parallel group, placebo-controlled trial. Randomisation, blinding OK, allocation seems to follow randomisation. King's College Hospital, St Pancras Hospital and Dulwich Hospital, London (UK).
Participants	Recurrent UTI. Number: 72 postmenopausal women. Age: > 60 years (mean 73.2 years).
Interventions	TREATMENT GROUP Oral oestriol (3 mg/d) for 6 months, followed for a further 6 months after treatment.  CONTROL GROUP Placebo.
Outcomes	1. Percentage of women remaining infection-free (dichotomous). 2. Breast tenderness (dichotomous). 3. Vaginal bleeding (dichotomous).
Notes	Definition of RUTI: at least UTI. Twenty-two women were unable to complete the trial. Reasons for early discontinuation in the oestriol group (n = 13) were major protocol violation (n = 4); hospital admission (n = 2); bleeding (n = 2); cerebrovascular accident (n = 2); poor compliance; adverse experiences; and depression. Early discontinuation reasons in the placebo group (n = 9) included femur fracture (n = 2); poor compliance; major protocol violation; septicaemia; cerebrovascular accident; left arm paresis; adverse experiences and general decline in health.
Allocation concealment	B – Unclear

**Study**                      **Eriksen 1999**

Methods	Multi-centred (15), randomised, open, parallel group study. Country: Norway. Time frame: 15 October 1993 to 5 June 1996. Not blinded.
Participants	Number: 108 women. Age: $\geq$ 2 years after spontaneous or surgical menopause. UTIs: $\geq$ 3 treated during previous 12 months and had normal urine.
Interventions	TREATMENT GROUP Estradiol-releasing silicone vaginal ring (Estring) (2 mg oestriol) was carried vaginally for 12 weeks.  CONTROL GROUP Untreated controlled group.  Duration of treatment: 36 weeks for Estring group, and until first recurrence for the control group.
Outcomes	1. Proportion of women with recurrent UTI (dichotomous). 2. Proportion of women remaining free of UTI (dichotomous). 3. Vaginal mucosal atrophy (dichotomous). 4. Vaginal pH (continuous). 5. Vaginal bleeding (dichotomous).

## Characteristics of included studies (Continued)

Notes Quality is lower than the others.  
“Fourteen of the 108 subjects (9 subjects treated with the vaginal ring and 5 with no oestrogen treatment) were excluded from the per-protocol analysis of time to first recurrence. In addition, 3 subjects, all from the Estring group, were excluded from the per-protocol analysis for secondary variables. Five subjects (9%) withdrew from the ring group and 1 subject (2%) withdrew from the control group before completion of the 36-week study period or before first recurrence (control group). The reason for withdrawal was “local discomfort“ (3 subjects in the Estring group) or “subject’s own wish“ (2 subjects in the Estring group and 1 subject in the control group)”.

Allocation concealment B – Unclear

### Study Kirkengen 1992

Methods Randomised, double-blind, group-comparative, placebo-controlled trial.  
Block randomisation.  
In-patients at the Red Cross Clinic and patients being treated by general practitioners in Oslo.

Participants Number: 40 postmenopausal women.  
Age: median 78 years (66-91).

Interventions TREATMENT GROUP  
Single daily 3 mg oral oestriol every morning during the first 4 weeks and 1 mg/d during the last 8 weeks of the treatment period.  
  
CONTROL GROUP  
Placebo in the same schedule as treatment group.

Outcomes 1. Proportion of women with recurrent UTI (dichotomous).  
2. Vaginal pH (continuous).

Notes Definition of RUTI: at least one episode with a repeat infection within two weeks or at least three episodes during the previous year.

Allocation concealment B – Unclear

### Study Kjaergaard 1990

Methods Randomised double-blind, control trial.

Participants Number: 21 postmenopausal women.

Interventions TREATMENT GROUP  
Vaginal estradiol.  
  
CONTROL GROUP  
Placebo.

Outcomes 1. Median of UTI at the end of the study period.  
2. Patient satisfaction.

Notes

Allocation concealment B – Unclear

### Study Ouslander 2001

Methods Randomised placebo-controlled trial.  
5 community nursing homes in USA.  
Allocation concealment adequate.

Participants Number: 32 incontinent female residents.  
Age: average 88 years.

Interventions TREATMENT GROUP

**Characteristics of included studies (Continued)**

Oral oestrogen (0.625 mg/d) combined with progesterone (2.5 mg/d) for 6 months.

**CONTROL GROUP**

Placebo for 6 months.

Outcomes	<ol style="list-style-type: none"> <li>1. Percentage of vaginal superficial cells (dichotomous).</li> <li>2. Vaginal parabasal cells (continuous).</li> <li>3. Vaginal pH (continuous).</li> <li>4. Bacteriuria and pyuria (dichotomous).</li> <li>5. Presence of lactobacillus (dichotomous).</li> <li>6. Breast discomfort (dichotomous).</li> </ol>
Notes	<p>Definition of RUTI: prevalence of bacteriuria.</p> <p>Three (9%) dropped out before the 3-month examination (two active, one placebo), leaving 29 subjects who had 3-month measures (13 active and 16 placebo; 91% of those enrolled). An additional eight (25%) dropped out before the 6-month examination (four active, four placebo), leaving 21 subjects who had 6-month measures (nine active and 12 placebo; 66% of those enrolled). Reasons for dropping out were primarily various acute illnesses (which resulted in two deaths)</p>
Allocation concealment	B – Unclear

**Study****Raz 1993**

Methods	<p>Randomised, double-blind, placebo-controlled trial.</p> <p>Infectious Diseases Clinic, Central Emek Hospital, Afula, Israel.</p>
Participants	<p>Number: 93 postmenopausal women.</p> <p>History of 3 or more microbiologically confirmed symptomatic episodes or UTI during the previous year.</p>
Interventions	<p><b>TREATMENT GROUP</b></p> <p>Topically applied intravaginal oestriol cream of 0.5 mg each night for 2 weeks followed by twice-weekly applications for 8 months.</p> <p><b>CONTROL GROUP</b></p> <p>Placebo applied in a same manner as treatment.</p>
Outcomes	<ol style="list-style-type: none"> <li>1. Incidence of UTI (dichotomous).</li> <li>2. Proportion of patients remaining free of UTI (dichotomous).</li> <li>3. Presence of lactobacillus (dichotomous).</li> <li>4. Vaginal pH (continuous).</li> <li>5. Number of episodes of UTI/patient/year (continuous).</li> </ol>
Notes	<p>Reasons for early withdrawal from the study: side effects in 10 women in the oestriol group and 4 in the placebo group; lack of compliance with follow-up in 3 and 5 women, respectively; death due to myocardial infarction in 1 oestriol-treated patient; and failure to respond to topical prophylaxis necessitating systemic antimicrobial prophylaxis for recurrent infections in 10 women in the placebo group</p>
Allocation concealment	B – Unclear

**Study****Raz 2003**

Methods	<p>Double-blind, double dummy, randomised trial.</p> <p>Outpatient clinics (3) in northern Israel.</p>
Participants	<p>Number: 171 postmenopausal women.</p> <p>History of recurrent UTI.</p>
Interventions	<p><b>TREATMENT GROUP</b></p> <p>Oestriol-containing vaginal pessary.</p> <p>Daily for 2 weeks, and then once every 2 weeks for 9 months together with oral placebo capsules each night during the same period.</p>

**CONTROL GROUP**

Nitrofurantoin macrocrystal (NM).

A capsule of NM nightly for 9 months together with a placebo vaginal pessary daily for 2 weeks.

Outcomes	1. Number of UTI episodes/patient/(continuous). 2. Proportion of women who remained free of UTI (dichotomous). 3. Percentage of superficial cells (dichotomous). 4. Lactobacillus colonisation (dichotomous).
Notes	Twenty-seven patients in the oestriol group and 23 in the NM group dropped out. Reasons for dropout included adverse events (9 patients in the oestriol group and 14 in the NM group), lack of compliance with the treatment regimen (13 and 6, respectively), and intermittent illness (3 and 2, respectively)
Allocation concealment	B – Unclear

<b>Study</b>	<b>Xu 2001</b>
Methods	Randomised control trial. Gynaecological units.
Participants	Number: 45 postmenopausal women. History of recurrent UTI.
Interventions	<b>TREATMENT GROUP</b> Vaginal estrogens (intravaginal premarin cream) for 3 months. Number: 30.  <b>CONTROL GROUP</b> Oral ofloxacin 600 mg/d for 3 months. Number: 15.
Outcomes	1. UTI. 2. Adverse events. 3. Vaginal pH. 4. UTI two months after finishing the study.
Notes	
Allocation concealment	B – Unclear

**Characteristics of excluded studies**

<b>Study</b>	<b>Reason for exclusion</b>
Ayton 1996	Outcomes for urogenital atrophy in postmenopausal women, not about the treatment for recurrent UTI in postmenopausal women.
Brandberg 1987	The quality of this clinical trial was low. The primary outcomes were not reported.
Chompootaweep 1998	Outcomes for vaginal atrophy.
Henriksson 1996	The primary outcomes were not reported.
Marx 2004	Main outcomes were vaginal atrophy. Participants did not meet inclusion criteria for this systematic review (no previous history of UTI).
Molander 1990	Main outcomes were related to vaginal atrophy.
Notelovitz 1995	Participants did not meet the inclusion criteria for this review.
Orlander 1992	Not an RCT.

## Characteristics of excluded studies (Continued)

### ADDITIONAL TABLES

Table 01. Electronic search strategies

Database	Search terms
CENTRAL	<p>#1 MeSH descriptor Urinary Tract Infections explode all trees in MeSH products #2 urin* near infect* in All Fields in all products #3 uti or utis in All Fields in all products #4 bacteriuria in All Fields in all products #5 pyuria in All Fields in all products #6 (#1 OR #2 OR #3 OR #4 OR #5) #7 MeSH descriptor Estrogens explode all trees in MeSH products #8 MeSH descriptor Estrogen Replacement Therapy, this term only in MeSH products #9 estrogen* in All Fields in all products #10 oestrogen* in All Fields in all products #11 ERT in All Fields in all products #12 (#7 OR #8 OR #9 OR #10 OR #11) #13 (#6 AND #12)</p>
MEDLINE	<p>1. exp urinary tract infections/ 2. (urin\$ adj3 infection\$).tw. 3. uti\$.tw. 4. bacteriuria\$.tw. 5. pyuria.tw. 6. or/1-5 7. exp Estrogens/ 8. Estrogen Replacement Therapy/ 9. estrogen\$.tw. 10. oestrogen\$.tw. 11. ert.tw. 12. or/7-11</p>
EMBASE	<p>1. exp Urinary Tract Infection/ 2. (urin\$ adj3 infection\$).tw. 3. uti\$.tw. 4. exp BACTERIURIA/ 5. bacteriuria\$.tw. 6. exp PYURIA/ 7. pyuria.tw. 8. or/1-7 9. Estrogen/ 10. Estrogen Therapy/ 11. estrogen\$.tw. 12. oestrogen\$.tw. 13. ert.tw. 14. or/9-13 15. 8 and 14</p>

## ANALYSES

### Comparison 01. Oral oestrogens versus placebo

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 UTI at the end of the treatment period	4	2798	Relative Risk (Random) 95% CI	1.08 [0.88, 1.33]
02 Vaginal pH	2	62	Weighted Mean Difference (Random) 95% CI	-1.00 [-1.43, -0.57]
03 Lactobacillus positive			Relative Risk (Random) 95% CI	Totals not selected
04 All adverse events	2	104	Relative Risk (Random) 95% CI	5.11 [1.39, 18.76]

### Comparison 02. Vaginal oestrogens versus placebo/no treatment

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 UTI at the end of the treatment period			Relative Risk (Random) 95% CI	Totals not selected
02 Vaginal pH			Weighted Mean Difference (Random) 95% CI	Totals not selected
03 Lactobacillus positive			Relative Risk (Random) 95% CI	Totals not selected
04 Any adverse events	2	201	Relative Risk (Random) 95% CI	4.72 [0.67, 33.53]

### Comparison 03. Vaginal oestrogens versus antibiotics

Outcome title	No. of studies	No. of participants	Statistical method	Effect size
01 UTI			Relative Risk (Random) 95% CI	Totals not selected
02 Vaginal pH	2	213	Weighted Mean Difference (Random) 95% CI	-1.69 [-4.24, 0.85]
03 Lactobacillus positive	2	213	Relative Risk (Random) 95% CI	4.02 [0.25, 65.17]
04 Adverse events (burning, itching or vaginal bleeding)	2	216	Relative Risk (Random) 95% CI	12.86 [1.75, 94.29]

## COVER SHEET

<b>Title</b>	Oestrogens for preventing recurrent urinary tract infection in postmenopausal women
<b>Authors</b>	Perrotta C, Aznar M, Mejia R, Albert X, Ng CW
<b>Contribution of author(s)</b>	CP - Screen search results, select studies, assess quality, data extraction, data analysis and writing the final version of the review. CWN - Search and retrieve relevant articles, did data extraction and entered into RevMan. MA - Data extraction and quality assessments and collaborated in the final version of the review. RM - Collaborated preparing the discussion and revising the review. XA - Prepared the protocol and revised the final version of the review.
<b>Issue protocol first published</b>	2005/1
<b>Review first published</b>	2008/2
<b>Date of most recent amendment</b>	05 February 2008
<b>Date of most recent SUBSTANTIVE amendment</b>	31 January 2008
<b>What's New</b>	Information not supplied by author

**Date new studies sought but none found** Information not supplied by author

**Date new studies found but not yet included/excluded** Information not supplied by author

**Date new studies found and included/excluded** Information not supplied by author

**Date authors' conclusions section amended** Information not supplied by author

**Contact address** Dr Carla Perrotta  
Woodview House  
UCD School of Public Health and Population Sciences  
Belfield  
Dublin  
4  
IRELAND  
E-mail: carla.perrotta@ucd.ie  
Tel: +353 1 716 3180  
Fax: +353 1 716 7407

**DOI** 10.1002/14651858.CD005131.pub2

**Cochrane Library number** CD005131

**Editorial group** Cochrane Renal Group

**Editorial group code** HM-RENAL


## GRAPHS AND OTHER TABLES

### Analysis 01.01. Comparison 01 Oral oestrogens versus placebo, Outcome 01 UTI at the end of the treatment period

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women

Comparison: 01 Oral oestrogens versus placebo

Outcome: 01 UTI at the end of the treatment period




### Analysis 01.02. Comparison 01 Oral oestrogens versus placebo, Outcome 02 Vaginal pH

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women

Comparison: 01 Oral oestrogens versus placebo

Outcome: 02 Vaginal pH




### Analysis 01.03. Comparison 01 Oral oestrogens versus placebo, Outcome 03 Lactobacillus positive

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women

Comparison: 01 Oral oestrogens versus placebo

Outcome: 03 Lactobacillus positive




### Analysis 01.04. Comparison 01 Oral oestrogens versus placebo, Outcome 04 All adverse events

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women


Comparison: 01 Oral oestrogens versus placebo

Outcome: 04 All adverse events




**Analysis 02.01. Comparison 02 Vaginal oestrogens versus placebo/no treatment, Outcome 01 UTI at the end of the treatment period**

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women  
 Comparison: 02 Vaginal oestrogens versus placebo/no treatment  
 Outcome: 01 UTI at the end of the treatment period




**Analysis 02.02. Comparison 02 Vaginal oestrogens versus placebo/no treatment, Outcome 02 Vaginal pH**

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women  
 Comparison: 02 Vaginal oestrogens versus placebo/no treatment  
 Outcome: 02 Vaginal pH



**Analysis 02.03. Comparison 02 Vaginal oestrogens versus placebo/no treatment, Outcome 03 Lactobacillus positive**

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women  
 Comparison: 02 Vaginal oestrogens versus placebo/no treatment  
 Outcome: 03 Lactobacillus positive




**Analysis 02.04. Comparison 02 Vaginal oestrogens versus placebo/no treatment, Outcome 04 Any adverse events**

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women

Comparison: 02 Vaginal oestrogens versus placebo/no treatment

Outcome: 04 Any adverse events




**Analysis 03.01. Comparison 03 Vaginal oestrogens versus antibiotics, Outcome 01 UTI**

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women

Comparison: 03 Vaginal oestrogens versus antibiotics

Outcome: 01 UTI




### Analysis 03.02. Comparison 03 Vaginal oestrogens versus antibiotics, Outcome 02 Vaginal pH

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women

Comparison: 03 Vaginal oestrogens versus antibiotics

Outcome: 02 Vaginal pH




### Analysis 03.03. Comparison 03 Vaginal oestrogens versus antibiotics, Outcome 03 Lactobacillus positive

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women

Comparison: 03 Vaginal oestrogens versus antibiotics

Outcome: 03 Lactobacillus positive



**Analysis 03.04. Comparison 03 Vaginal oestrogens versus antibiotics, Outcome 04 Adverse events (burning, itching or vaginal bleeding)**

Review: Oestrogens for preventing recurrent urinary tract infection in postmenopausal women

Comparison: 03 Vaginal oestrogens versus antibiotics

Outcome: 04 Adverse events (burning, itching or vaginal bleeding)

